Pfizer Animal Health says it intends to acquire the biotech Embrex for $155 million, primarily for access to its Inovoject vaccine-delivery system. The deal is expected to be completed in the first quarter of next year.
Published in Brief:
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore